These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6138470)

  • 21. The sympathetic nervous system and ischaemic heart disease.
    Remme WJ
    Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. beta-blockade, atrial natriuretic peptide and exercise.
    Kantola I; Tarssanen L; Scheinin M; Ruskoaho H; Viinamäki O; Kaila T
    Int J Clin Pharmacol Ther; 1996 Jan; 34(1):12-6. PubMed ID: 8688991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Does chronic oral treatment with beta-receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?].
    Günnicker M; Brinkmann M; Freund U; Piotrowski J; Schieffer M; Velser U
    Herz; 1995 Dec; 20(6):399-411. PubMed ID: 8582699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central hemodynamics of beta-adrenoceptor blocking drugs: beta 1 selectivity versus intrinsic sympathomimetic activity.
    Svendsen TL
    J Cardiovasc Pharmacol; 1983; 5 Suppl 1():S21-5. PubMed ID: 6188916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists.
    Nederfors T
    Swed Dent J Suppl; 1996; 116():1-70. PubMed ID: 8813731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abrupt propranolol withdrawal and myocardial contractility. A study of effects in normal man.
    Pantano JA; Lee YC
    Arch Intern Med; 1976 Aug; 136(8):867-71. PubMed ID: 949186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats.
    Brynne L; Paalzow LK; Karlsson MO
    J Pharmacol Exp Ther; 1999 Aug; 290(2):664-71. PubMed ID: 10411576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of withdrawal of beta-adrenergic blockade on intermittent claudication.
    Lepäntalo M; von Knorring J; Lindfors O; Scheinin TM
    Angiology; 1983 Jun; 34(6):401-11. PubMed ID: 6135376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Withdrawal effects following interruption of antihypertensive drugs. II. Coronary rebound phenomenon with antihypertensive drugs used in coronary heart disease therapy (author's transl)].
    Laham E
    Sem Hop; 1979 Dec 8-15; 55(41-42):1905-8. PubMed ID: 231311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-adrenoceptor-blocking drugs in the elderly.
    Tregaskis BF; McDevitt DG
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S25-8. PubMed ID: 11527132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sympathetic reinnervation, exercise performance and effects of beta-adrenergic blockade in cardiac transplant recipients.
    Bengel FM; Ueberfuhr P; Karja J; Schreiber K; Nekolla SG; Reichart B; Schwaiger M
    Eur Heart J; 2004 Oct; 25(19):1726-33. PubMed ID: 15451151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Withdrawal symptoms after discontinuation of beta-adrenolytic drugs].
    Markiewicz A; Karel M
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1452-5. PubMed ID: 2421274
    [No Abstract]   [Full Text] [Related]  

  • 34. Rebound phenomena following withdrawal of long-term beta-adrenoceptor blockade.
    Hjemdahl P; Olsson G
    Acta Med Scand Suppl; 1982; 665():43-7. PubMed ID: 6130674
    [No Abstract]   [Full Text] [Related]  

  • 35. The phenomenon of beta-adrenergic hypersensitivity following propranolol withdrawal studied in normal subjects.
    Kiyingi KS; Shaw J
    Eur J Clin Pharmacol; 1984; 27(4):423-8. PubMed ID: 6097455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers.
    Walden RJ; Tomlinson B; Graham B; Smith C; Betteridge DJ; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):547-56. PubMed ID: 1981317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiac hyper- and hyporesponsiveness after pindolol withdrawal.
    Rangno RE; Langlois S; Stewart J
    Clin Pharmacol Ther; 1982 May; 31(5):564-71. PubMed ID: 7075106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-adrenergic blocker withdrawal.
    Frishman WH
    Am J Cardiol; 1987 May; 59(13):26F-32F. PubMed ID: 2883874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adrenergic hypersensitivity after beta-blocker withdrawal.
    Ross PJ; Lewis MJ; Sheridan DJ; Henderson AH
    Br Heart J; 1981 Jun; 45(6):637-42. PubMed ID: 6114739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.
    Walden RJ; Tomlinson B; Graham B; Liu JB; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):557-65. PubMed ID: 1981318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.